Extended Data Fig. 6: in vivo study of conatumumab-mediated senolysis.
From: cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
a-b. Tumor growth of A549 (a) and SK-Hep1 (b) cells in flanks of Balb/c nude mice subcutaneously injected with 5 million cells. When tumors reached approximately 150mm3, assigned to either vehicle control, 25 mg/kg alisertib, conatumumab (5 µg/dose for SK-Hep1, 10 µg/dose for A549) and combination (6 mice per group for A549, 8 mice per group for SK-Hep1). The data are presented as mean ± s.e.m. Two-way ANOVA test was applied for xenograft experiments (a, b) for statistical analysis c, Fixed tissues were dehydrated and embedded in paraffin. Sections of 2-4 µm were prepared and immunostained with P21 to indicate senescent cells in the tumors of A549 and Sk-Hep1. The black scale bars present 50 µm. d-e, Immunohistochemistry analysis of P21 expression. Error bars in this figure panel d,e represent as mean ± standard deviations, N = 12 tumor tissue slides, statistical significance was calculated by two-tailed t-test.
